Journal of Virology & Antiviral ResearchISSN: 2324-8955

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Virol Antivir Res Vol: 3 Issue: 2

Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study

Hiroki Nishikawa1, Hirayuki Enomoto2, Masaki Saito2, Nobuhiro Aizawa2, Yasuhiro Tsuda3, Kazuhide Higuchi3, Kazuichi Okazaki4, Toshihito Seki4, Soo Ryang Kim5, Yasushi Hongo6, Hisato Jyomura7, Naoshi Nishida8, Masatoshi Kudo8, Yukio Osaki1 and Shuhei Nishiguchi2
1Department Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
2Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
3Second Department of Internal Medicine, Osaka Medical College, Osaka, Japan
4Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan
5Department of Internal Medicine, Kobe Asahi Hospital, Hyogo, Japan
6Department of Gastroenterology and Hepatology, Hirakata City Hospital, Osaka, Japan
7Wakakoukai Medical Clinic, Osaka, Japan
8Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan
Corresponding author : Hiroki Nishikawa
MD, Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan
Tel: +81-6-6774-5111; Fax: +81-6-6774-5131
E-mail: [email protected]
Received: May 23, 2014 Accepted: June 24, 2014 Published: June 26, 2014
Citation: Nishikawa H, Hirayuki E, Saito M, Aizawa N, Tsuda Y, et al.(2014) Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study. J Virol Antivir Res 3:2. doi:10.4172/2324-8955.1000125

Abstract

Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study

Background: We previously reported response-guided therapy (RGT) of peginterferon (Peg-IFN)-2a with or without ribavirin (RBV) for chronic hepatitis C (CHC) of genotype 1b (a multicenter randomized trial, ReGIT-J study). Here, we performed a subgroup analysis of the ReGIT-J study according to age. Methods: The sustained virological response (SVR) rate and the treatment discontinuation rate were calculated in both groups. Results: In the elderly group (65 years, n=54), the SVR rate in the RGT group was higher than in the non- RGT group (50% [9/18] vs 36% [8/22], P=0.385). Similarly, in the control group (<65 years, n=132), the SVR rate in the RGT group was higher than in the non-RGT group (65% [31/48] vs 50% [27/54], P=0.138). In the elderly group, the discontinuation rate in the RGT group was almost significantly lower than in the non-RGT group (0% [0/18] vs 18% [4/22], P=0.057), whereas in the control group, the difference between the groups was not significant (4% [2/48] vs 13% [7/54], P=0.118). Furthermore, in all subgroup analyses, there was no significant difference between the elderly and control groups in terms of treatment response. Conclusion: Our proposed RGT was well tolerated in elderly CHC patients treated with Peg-IFN-2a with or without RBV.

Keywords: Elderly patients; Drug safety; Sustained virological response; Peginterferon -2a and Ribavirin; Response-guided therapy

Track Your Manuscript

Share This Page

Media Partners